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Increased oxidative stress is a major contributor to the development and progression of
heart failure, however, our knowledge on the role of the distinct NADPH oxidase (NOX)
isoenzymes, especially on NOX4 is controversial. Therefore, we aimed to characterize
NOX4 expression in human samples from healthy and failing hearts. Explanted human
heart samples (left and right ventricular, and septal regions) were obtained from patients
suffering from heart failure of ischemic or dilated origin. Control samples were obtained
from donor hearts that were not used for transplantation. Deep RNA sequencing of the
cardiac transcriptome indicated extensive alternative splicing of the NOX4 gene in heart
failure as compared to samples from healthy donor hearts. Long distance PCR analysis
with a universal 5′-3′ end primer pair, allowing amplification of different splice variants,
confirmed the presence of the splice variants. To assess translation of the alternatively
spliced transcripts we determined protein expression of NOX4 by using a specific
antibody recognizing a conserved region in all variants. Western blot analysis showed
up-regulation of the full-length NOX4 in ischemic cardiomyopathy samples and confirmed
presence of shorter isoforms both in control and failing samples with disease-associated
expression pattern. We describe here for the first time that NOX4 undergoes extensive
alternative splicing in human hearts which gives rise to the expression of different enzyme
isoforms. The full length NOX4 is significantly upregulated in ischemic cardiomyopathy
suggesting a role for NOX4 in ROS production during heart failure.
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INTRODUCTION
In spite of an overall decrease in coronary artery disease-related mortality, the number of patients
suffering from heart failure is increasing steeply in aging societies (Rich, 2001; Bui et al., 2011).
Aging has a considerable impact on the heart and the vasculature, partially by promoting a
prooxidative milieu (Csiszar et al., 2002; Donato et al., 2007; Dai et al., 2012; Martin-Fernandez and
Gredilla, 2016). In accordance, increased oxidative stress and subsequent redox imbalance has been
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implicated in the development and progression of heart failure
(Keith et al., 1998; Ungvari et al., 2005). Reactive oxygen
species (ROS) production at a basal level may induce profound
adaptive changes in intracellular pathways, however, higher
concentrations of ROS induces tissue damage. ROS are derived
from several intracellular sources, including mitochondrial
respiratory complexes, NADPH oxidases (NOX), xanthine
oxidase, mono-amino oxidases, and uncoupled nitric oxide
synthase, among others. Although, the majority of these enzymes
generates ROS as a by-product of dysfunctional activity, the
only known role of the NOX family is ROS production.
This fact makes NOXs intriguing targets for pharmacotherapy,
allowing selective targeting of disease-specific ROS production
(Altenhofer et al., 2012, 2015). To our present knowledge, the
NOX family is composed of five different enzymes (NOX1,
NOX2, NOX3, NOX4, and NOX5) and five subunits, known as
phox proteins (Leto et al., 2009; Sirokmany et al., 2016). NOX
enzymes have been proven to be involved both in experimental
models (Li et al., 2002; Byrne et al., 2003) and in humans suffering
from advanced heart failure (Heymes et al., 2003). In a landmark
paper, Heymes et al. described an overall increase in NOX activity
in human failing hearts, however, surprisingly, they found no
change in the overall level of expression of oxidase subunits in
failing hearts (Heymes et al., 2003), suggesting a novel NOX as a
potential source of ROS production.
The NADPH oxidase 4 (NOX4) isoenzyme has been
discovered in 2000, in the renal cortex (Geiszt et al., 2000).
However, it has been proven later that many other cell
types (including cardiomyocytes) also express NOX4 (Byrne
et al., 2003; Varga et al., 2013). According to a recent study,
mitochondrial NOX4 activity is a critical regulator of fatty acid β-
oxidation in macrophages (Moon et al., 2016), an effect that has
been also described in cardiomyocytes (Nabeebaccus et al., 2015).
Interestingly, in contrast to the inducible NOX2, NOX4
displays constitutive mRNA expression, which is fine-tuned by
delicate epigenetic mechanisms, involving microRNA-dependent
posttranscriptional repression (Varga et al., 2013). In addition,
NOX4 might have alternative mRNA splice variants (Goyal et al.,
2005) that might further complicate understanding the role of
NOX4 in normal physiology and in pathological conditions.
Accordingly, in the last decade, several conflicting results have
been published, giving rise to many controversy on the NOX4
field. So far, both superoxide and hydrogen peroxide have been
proposed as a product of NOX4 activity (Shiose et al., 2001; Takac
et al., 2011; Nisimoto et al., 2014). Mitochondrial localization of
NOX4 is still a question of debate (Hirschhauser et al., 2015),
while a recent paper suggest nuclear/perinuclear localization of
NOX4 (Matsushima et al., 2013). In addition, NOX4 has been
described both as detrimental and protective in mouse models of
heart failure (Kuroda et al., 2010; Zhang et al., 2010; Nabeebaccus
et al., 2015; Zhao et al., 2015; Matsushima et al., 2016).
Therefore, here we aimed to characterize and assess the
expression of NOX4 in the failing human hearts with unbiased
transcriptomics methods followed by validations at the protein
level. In addition, we put special emphasis to characterize
alternative splicing of NOX4 in healthy and failing human
hearts.
MATERIALS AND METHODS
Study Design
All experimental procedures were done in accordance with the
ethical standards of the responsible institutional and national
committee on human experimentation, adhering to the Helsinki
Declaration (1975).Written informed consent was obtained from
all patients involved in the study according to the protocol
approved by the Local Ethics Committees of the Institute
of Cardiology, Warszawa, Poland and Hospital Universitario
Puerta de Hierro Majadahonda, Madrid, Spain (IK-NP-0021-
24/1426/14, 272-19/12/11). Healthy human hearts were obtained
from organ donor patients (CONT, n = 5) whose hearts were
not used for transplantation due to technical reasons (e.g.,
donor/recipient incompatibility). The donors did not have any
relevant previous cardiological history or any abnormalities in
ECG and echocardiography (LV dimensions/contractility within
normal ranges). Explanted failing hearts were obtained from
patients suffering from end-stage, advanced heart failure of non-
ischemic (i.e., dilated cardiomyopathy, DCM, n= 5) or ischemic
(ICM, n= 5) etiology.
Preparation of Tissue Samples
Human tissue samples were taken at the time of heart explanation
(avoiding scarred, fibrotic, or adipose tissue, endocardium,
epicardium, or coronary vessels). The samples were rinsed
immediately in saline, blotted dry, frozen in liquid nitrogen and
kept at−80◦C until further processing.
Rat heart and kidney tissues were harvested from male Wistar
rats (250–300 g). The samples were snap frozen and crushed to
small pieces in a mortar with pestle in liquid nitrogen.
RNA Sequencing
Whole transcriptome sequencing was performed, and data
regarding NOX4 transcript were used and evaluated in the
present project. Total RNA was isolated after homogenization
of frozen myocardial samples using RNAeasy columns (Qiagen)
as previously described (Lopez-Olaneta et al., 2014). RNA
integrity was assessed using an Agilent Bioanalyzer and reverse-
transcribed. Amplified cDNA (1 µg) was sonicated to an
average size of 100–300 bp and used with the TruSeq DNA
Sample Preparation v2 Kit (Illumina) to generate index-tagged
sequencing libraries. Libraries were applied to Genome Analyzer
IIx (Illumina) followed by standard RNA sequencing protocol to
generate 80–120M of paired end 75 bp-long reads. Reads were
further processed using the CASAVA package (Illumina) and
cutadapt software (Extended Experimental Procedure). Resulting
reads were mapped to the ensemble human genome v75 and
quantified on the transcriptome using RSEM (Li and Dewey,
2011). FromRSEMwe used the IsoPct information (percentage of
the gene expression accounted by each transcript) in each sample
to identify isoforms potentially undergoing alternative splicing.
Long-Distance PCR Analysis of
Alternatively Spliced mRNA Transcripts
Total RNA was isolated from homogenized left ventricle (LV)
of the CONT, DCM, or ICM patients with the guanidinium
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thiocyanate-phenol-chloroform extraction method, as described
earlier (Baan et al., 2015). RNA was reverse transcribed
with MMLV-Reverse Transcriptase (Invitrogen, USA). For the
detection of the alternatively spliced transcript levels of NOX4,
long-distance PCR was carried out with a high fidelity Pfu
polymerase (G-Biosciences, USA) with cycling conditions set
as an initial denaturation step for 5min at 95◦C, followed
by 40 cycles of 30 s at 95◦C for template denaturation,
30 s for annealing phase at 55◦C, and 3.5min at 72◦C for
extension. Length of the specific PCR products was verified
on 1.5% agarose gels stained with GelRed (Biotium, USA).
Primer pairs for the long distance amplification of NOX4
were designed to amplify from a conserved region from all
splice variants. The primer sequences were the following:
forward primer 5′-TGCTGTATAACCAAGGGCCA-3′, reverse
primer 5′-GGTCCACAACAGAAAACACCA-3′. The primers
were designed by Primer 3 Input (version 0.4.0) software and
tested to avoid primer dimer formation, unspecific amplification
and self-priming formation.
Western Blot Analysis of NOX4
In order to investigate whether NOX4 expression is altered
at the protein level in the failing human heart, western
blot analysis was performed. Frozen tissue samples from left
ventricle (LV) and right ventricle (RV) as well as from inter-
ventricular septum (IVS) were homogenized in NP-40 lysis buffer
(150mM NaCl, 50mM Tris, 1% NP-40) for NOX4 or with
RIPA buffer for ERK with a tissue to homogenization buffer
ratio of 1:4 containing protease and phosphatase inhibitors
(AEBSF, Aprotinin, Bestatin, E-64, Leupeptin, Pepstatin A,
sodium orthovanadate and sodium fluoride) (Sigma-Aldrich,
St. Louis, MO, USA). Protein concentrations were assessed
by the bicinchoninic acid method using the provided bovine
serum albumin as standard (Pierce Biotechnologies, USA).
Equal amounts of protein were loaded from each sample onto
10% SDS-polyacrylamide gels. For optimal results, in case of
NOX4 blots, samples were mixed with Laemmli sample buffer
without using reducing agents or sample boiling. After separation
by electrophoresis, proteins were transferred (wet transfer,
2.5 h) onto nitrocellulose membrane (Amersham Biosciences,
Piscataway, USA). Transfer was controlled by Ponceau S
staining. The membrane was blocked with 5% non-fat dry
milk in 0.1% TBS-T overnight at 4◦C. After the blocking
step, the membrane was incubated with a rabbit polyclonal
primary antibody (dissolved in 1% non-fat dry milk in 0.1%
TBS-T, 1:1,000 dilution) against NOX4 (NB110-58851, Novus
Biologicals, United Kingdom)—reported to specifically recognize
NOX4 protein (Basuroy et al., 2009; Maalouf et al., 2012; Siuda
et al., 2012)—, or by a mouse monoclonal antibody recognizing
pERK1/2 or total ERK (9106 and 9107 Cell Signaling technology,
Danvers, MA, USA) for 2 h at room temperature (NOX4) or
overnight at 4◦C (ERK), followed by washing with 0.1% TBS-
T (3 times for 10min). After washing, the membrane was
incubated with a secondary antibody (horseradish peroxidase-
conjugated affinity purified goat anti-rabbit, 1:5,000 dilution,
Dako, Denmark; horseradish peroxidase-conjugated affinity
purified horse anti-mouse, 1:5,000 dilution, Cell Signaling
TABLE 1 | Clinical characteristics of study population.
CON DCM ICM
Number of samples 5 5 5
Gender (female/male) 3/2 2/3 4/1
Age (year) 29 ± 9 39 ± 10 57 ± 11
NYHA functional class III/IV, n n.a. 0/5 3/2
LVED, mm n.a. 68 ± 4 71 ± 4
LVSD, mm n.a. 63 ± 5 61 ± 8
PW, mm n.a. 9.5 ± 0.5 10 ± 1.5
IVS, mm n.a. 10 ± 0.7 11 ± 1.5
LVEF, % n.a. 16 ± 3 23 ± 3
Values are given in mean ± S.E.M. CON, healthy control individuals; DCM, dilated
cardiomyopathy; ICM, ischemic cardiomyopathy; NYHA, New York Heart Association;
LVED, left ventricular end-diastolic diameter; LVSD, left ventricular end-systolic diameter;
PW, posterior wall thickness; IVS, interventricular septum thickness; LVEF, left ventricular
ejection fraction; n.a., not applicable.
Technology, USA) in 1% non-fat dry milk in 0.1% TBS-T for 1 h
at room temperature. Then the membrane was washed again 3
times for 10min. For detection of the bands, the membrane was
incubated with ECL-Plus reagent (Amersham Biosciences, USA)
for 5min and then visualized. Band densities were evaluated by
using Quantity One software (Bio-Rad Imaging System, USA).
Equal loading was assessed by determining and normalizing to
GAPDH content of each sample. Briefly, stripped membranes
were probed with a primary antibody that recognizes GAPDH
(1:10,000 dilution, Cell Signaling Technology, Danvers, MA,
USA) for 2 h at room temperature, followed by washing with
TBS-T. Then the membrane was incubated with horseradish
peroxidase-conjugated affinity purified goat anti-rabbit antibody
(1:20,000 dilution) for 1 h at room temperature. The membrane
was washed again and band visualization and evaluation of band
densities were done as describe above. There was no significant
difference in GAPDH between groups.
Statistical Analysis
Statistical analysis was performed by one-way ANOVA using
Prism software (GraphPad Software, Inc., San Diego, USA), as
appropriate. All data were expressed as means ± S.E.M. For all
analyses, a p < 0.05 was considered statistically significant.
RESULTS
Study Patients
A detailed summary of clinical characteristics and medication of
study subjects are shown inTable 1. Patients of both genders were
enrolled in all groups. The age of patients suffering from ischemic
cardiomyopathy differed significantly from both control and
dilated cardiomyopathy patients as expected, since ischemic
cardiomyopathy leads to end-stage heart failure later and in older
population than dilated cardiomyopathy. DCMand ICMpatients
were in either New York Heart Association (NYHA) class III or
IV with no difference in major cardiac functional parameters.
All patients were treated with angiotensin-converting enzyme
inhibitors, beta-blockers and diuretics, however, aspirin and
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statins were only used in the treatment regime of ICM.
Control subjects received intravenous treatment composed
of very low catecholamine infusion (norepinephrine: 0.1–0.2
µg/kg/min, dopamine: 1–2 µg/kg/min). Adequate fluid balance
was maintained before heart explanation with intravenous fluids
(e.g., hydroxyethyl starch) and desmopressin.
NOX4 Transcript Variants Are Detected in
Human Hearts
The full length NOX4A consist of 18 different exons, giving
rise to the transcription of a 1,733 bp mRNA (Figure 1A).
The majority of isoforms lack one or more exons as a result
of alternative splicing. With an unbiased RNA sequencing
approach, we aimed to characterize the abundance of NOX4
splicing events. (Figure 1B) shows the detection of splice
variants (based on the Ensembl database) as detected by RNA
sequencing in control and failing human hearts. Currently there
are 17 NOX4-related entries, out of them 16 were detected in
control and failing human samples. Two sequences are only
retained introns (ENST0000524473 and ENST0000525278), and
ENST529343 has a premature stop codon potentially leading to
non-sense-mediated mRNA decay. However, the retained intron
sequence, ENST0000524473 was detectable in almost all samples.
It is also noteworthy that more alternative splicing events
were detected in the failing hearts (control average four events,
failing average 5.6 events). This was further confirmed by a long
distance PCR analysis that is shown on (Figure 1C). By using a
universal 5′-3′ end primer pair and a high fidelity enzyme and
longer amplification time, we were able the detect several NOX4
related transcripts, showing on one hand that the detected bands
are corresponding to the predicted and expected splice variants,
while on the other hand, it is also detectable on the agarose gel
picture that there is extensive splicing in the failing hearts when
compared to the healthy control left ventricular tissue.
NOX4 Protein Variants Are Present in
Failing Human Hearts with a Spatial and
Disease-Specific Distribution
To detect NOX4 variants at protein level, we used a polyclonal
antibody recognizing a conserved region of the protein (C-
terminal region) present in all transcript variants. During our
pilot experiments, we recognized that even in rodent samples
(rat kidney and heart) there is some extent of alternative splicing,
with a predominant expression of the 67-kDa band in both tissues
(Figure 2A).
However, in human hearts and using non-reducing loading
conditions this observation became more obvious (Figure 2B,
Supplementary Figure 1). Both in healthy control and failing
human hearts significant amounts of alternatively spliced forms
were detected. In ICM samples, the robust upregulation of
the 26-kDa form and downregulation of the 28-kDa form was
observed in all regions of the heart. Since the electrophoretic
mobility difference between the two forms is small, it is also
possible that we detected a posttranslational modification (e.g.,
deglycosylation—Goyal et al., 2005) of the same isoform. The
58-kDa form showed a significant upregulation in the IVS of
the ischemic failing hearts. In addition, we detected a significant
increase of the full length NOX4 (in non-reducing conditions the
major band is detected at the level of 90 kDa possibly as a complex
of a 67-kDa NOX4 with the p22 phox) in the IVS of ischemic
failing hearts that was associated with a tendency of upregulation
in the left ventricle as well (Figure 2C, Supplementary Figure 1).
In DCM samples, a significant upregulation of the 58-kDa
variant was seen, together with a tendency of increased full length
90-kDa complex, similarly to the ICM samples (Figure 2D,
Supplementary Figure 2).
To study the link between the observed difference in the
expression of the 28-kDa isoform and ERK1/2 phosphorylation
(Anilkumar et al., 2013), we performed pERK/ERKWestern blots
from left ventricular samples. We found significantly increased
phosphorylation of ERK1/2 in the ICM samples as compared to
CON samples, whereas there was an increase both in phosphor-
ERK and total-ERK levels when normalized to GAPDH in DCM
samples. These suggest activation of hypertrophic ERK signaling
independently from changes in NOX4D expression in these
samples (Supplementary Figure 3).
DISCUSSION
We described here for the first time that the NOX4 gene
undergoes alternative splicing in the human heart resulting in at
least three different protein isoforms. The full length NOX4 is
significantly upregulated in heart failure, while a smaller 28-kDa
isoform shows downregulation in ischemic failing hearts.
Alternative splicing is a critical process in RNA maturation
ensuring expression of functionally diverse proteins from
individual genes. Frequency of splicing events is estimated to
be really high, according to Pan and colleagues more than 85%
of the multi-exon genes contain at least one alternative splicing
event (Pan et al., 2008). Since alternative splicing is usually tissue
specific, and in many cases changes in alternative splicing occur
in a disease-specific manner during progression of the disease,
detection of splicing events could serve as a disease-specific
or disease stage-specific biomarker. In addition, regulation of
alternative splicing might affect disease outcome, pointing to the
theranostic potential of splicing events (Le et al., 2015). Although,
gene expression patterns in cardiac diseases have been extensively
studied over the last years, our overall knowledge in terms of
splicing events and the resulting protein isoforms and their
association with disease states is still very limited. The variability
in splicing may alter protein structure, thereby influencing
subcellular protein localization, and the overall function of
the particular protein. In the myocardium, alternative splicing
of sarcomeric genes, cardiac ion channels, and cell signaling
proteins have been reported so far, leading to the development
of cardiomyopathies and arrhythmias (Gao et al., 2011; Guo
et al., 2012; Lara-Pezzi et al., 2013; Maatz et al., 2014). Among
NOX family members, it is known that both NOX1 (Arakawa
et al., 2006) and NOX2 (Kuhns et al., 2010; Harrison et al.,
2012) enzymes undergo alternative splicing. Interestingly, in
lymphocytes of patients suffering from chronic granulomatosus
disease due to mutations in the CYBB gene (i.e., gp91 phox)
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FIGURE 1 | Known transcript variants of the NOX4 messenger RNA as original described in a human endothelial cell line by Goyal et al. (2005) (A). Splice variants
detected in control and failing human hearts by RNA sequencing (B). Each variant is annotated to an individual code in the Ensembl database. Black dots represent
the presence of the variant in the sample. Long distance PCR analysis to detect NOX4 transcripts (C). CON, control; ICM, ischemic cardiomyopathy; DCM, dilated
cardiomyopathy.
IFN-γ is capable of partially correcting mRNA processing defects
and improves splicing efficiency (Condino-Neto and Newburger,
2000). To date NOX4 transcripts variants have been reported
only in cell lines, including alveolar epithelial cells (Goyal et al.,
2005), vascular smooth muscle cells, endothelial cells, fibroblasts,
and cardiomyocytes (Anilkumar et al., 2013). Nevertheless,
the functional role of the transcripts is still largely unknown.
Anilkumar et al. have reported that the 28-kDa splice variant
(aka. NOX4D) is predominantly expressed in the nucleus, and
produces ROS that can activate kinase signaling cascades, such
as MAPK, and ROS-dependent extracellular-signal-regulated
kinases (ERK1/2) (Anilkumar et al., 2013), that may potentially
contribute to nuclear redox homeostasis (Hansen et al.,
2006). These observations are interesting in light of our
present results, since we observed a marked switch in the
expression/posttranslational modification of the 28-kDa isoform,
showing lower expression levels in the hearts of ischemic
cardiomyopathy patients. In our samples, however, we found
increased ERK phosphorylation both in ICM and DCM samples,
suggesting a potentially NOX4D-independent activation of
hypertrophic signaling during heart failure (Rose et al., 2010; Yeh
et al., 2010).
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FIGURE 2 | Alternative splicing of NOX4 in rat kidney and heart (A). Alternative splicing of NOX4 in human hearts (B). Quantitative evaluation of spliced NOX4
isoforms in ICM samples (C). Quantitative evaluation of spliced NOX4 isoforms in DCM samples (D). Data are mean ± S.E.M. n = 5/group. *p < 0.05. LV, left
ventricle; IVS, interventricular septum; RV, right ventricle; ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy.
Frontiers in Physiology | www.frontiersin.org 6 November 2017 | Volume 8 | Article 935
Varga et al. NOX4 Splicing in Heart Failure
Given the controversies in the NOX4 field, differences in
splicing events might also contribute to the different phenotypes
seen in the NOX4 knockout animals. So far four different knock-
out models have been published with deletions of different exons
(exons 1/2, exon 4, exon 9, or exons 14/15; for review please see:
Altenhofer et al., 2012). Therefore, it is possible that, in a tissue
specific manner, deletion of exon 4 or exon 9 may result in the
expression of NOX4 variants (NOX4D and E) leading to residual
NOX4 activity that complicates the interpretation of the results
seen in knock-out mice studies.
From a drug developmental point of view, alternative splicing
might be an important factor to consider as drug candidates
may have different effects on the spliced variants (e.g., a splice
event might underlie drug resistance de Necochea-Campion
et al., 2016). Therefore, NOX4 inhibitors currently under clinical
testing (e.g., GKT137831 from GenKyoTex S.A., VAS2870 from
Vasopharm GmbH, GLX351322 from Glucox Biotech AB—see
for review: Altenhofer et al., 2015) may also affect the activity of
splice variants differently that may in turn influence efficacy and
safety.
LIMITATIONS
A limitation of the present observational study is that our
conclusions are based on descriptive data from a limited set of
human samples. Due to the significant differences in the age of
the ICM patients and the healthy controls, we cannot rule out
the effect of age and the presence of different cardiovascular
comorbidities (Ferdinandy et al., 2007, 2014) on the observed
differences. Although mRNA and protein data clearly implicate
the presence of the alternative splice variants of NOX4, we
have not provided direct evidence by sequencing the proteins
after immunoprecipitation with the antibody used in the present
study.
CONCLUSIONS
In summary, our present study provides the first description
that the NOX4 mRNA undergoes alternative splicing in the
human heart, resulting in at least three different protein
isoforms. The full length NOX4 is significantly upregulated
due to heart failure that might contribute to ROS production
in the failing hearts, while a smaller 28-kDa isoform shows
downregulation in ischemic failing hearts possibly having
important roles in redox signaling of subcellular compartments.
Disease specific expression pattern of NOX4 isoforms may
provide new diagnostic and therapeutic targets in heart
failure, and disease-specific splicing events might represent
a new factor to consider when developing NOX4-modulator
drugs.
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Supplementary Figure 1 | Original Western blots for NOX4 (A), GAPDH (B), and
total protein staining by Ponceau S stain (C) in left ventricular (LV), right ventricular
(RV), and interventricular septal regions (IVS) of ischemic cardiomyopathy patients
(ICM).
Supplementary Figure 2 | Original Western blots for NOX4 (A), GAPDH (B), and
total protein staining by Ponceau S stain (C) in left ventricular (LV), right ventricular
(RV), and interventricular septal regions (IVS) of dilated cardiomyopathy patients
(DCM).
Supplementary Figure 3 | Original Western blots for phosphorylated ERK1/2,
total ERK1/2, GAPDH and total protein staining by Ponceau S stain in left
ventricular (LV) samples of ischemic (ICM—A) or dilated cardiomyopathy patients
(DCM—B), respectively. Data are mean ± S.E.M. n = 5/group. ∗p < 0.05.
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